论文部分内容阅读
用麻醉犬研究美托洛尔（Ｍｅｔ）光学异构体药动学—药效学结合模型。结果表明，ｉｇ（＋）Ｍｅｔ或（－）Ｍｅｔ后，其药动学符合二室模型，药动学参数Ｖｄ／Ｆ，ＣＬｓ／Ｆ和ＡＵＣ在两种Ｍｅｔ之间有显著性差异。（＋）Ｍｅｔ和（－）Ｍｅｔ的效应和血药浓度关系呈逆时针滞后环。引入效应室理论后，药效和效应室浓度之间的关系符合ＳｉｇｍｏｉｄＥｍａｘ模型。应用ＣＡＰＰ软件进行模型拟合，血药浓度的预测值和药效的预测值皆与其实测值较为接近。（＋）Ｍｅｔ抑制Ｖｍａｘ，ｄｐ／ｄｔｍａｘ及ＨＲ效应的Ｃｅ５０分别是（－）Ｍｅｔ的３７，６８，６３倍，证实（－）Ｍｅｔ对犬心脏的抑制作用强于（＋）Ｍｅｔ。
Pharmacokinetic-pharmacodynamic binding model of methotrexate in anesthetized dogs. The results showed that the pharmacokinetics of ig (+) Met or (-) Met followed the two - compartment model. The pharmacokinetic parameters Vd / F, CLs / F and AUC were significantly different between the two Met. (+) Met and (-) Met effect and plasma concentration showed a counterclockwise lag ring. The introduction of effect chamber theory, the relationship between efficacy and effect chamber concentration in line with Sigmoid Emax model. Using CAPP software for model fitting, the predictive value of plasma concentration and the predictive value of pharmacodynamics are close to the actual measured values. (+) Met inhibition of Vmax, dp / dtmax and HR effect of Ce50 were (3) ,6 6 8,6 3 times 3 times, confirmed that (-) Met inhibit the heart of dogs strong At (+) Met.